Icon of the Instituts for Quality and Efficiency in Health Care

[A22-67] Atezolizumab (NSCLC) – Benefit assessment according to § 35a SGB V

Last updated 05.01.2023

Project no.:
A22-67

Commission:
Commission awarded on 05.07.2022 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Adult patients with completely resected non-small cell lung cancer (NSCLC) at high risk of recurrence after platinum-based chemotherapy whose tumours express PD-L1 in ≥ 50% of the tumour cells and who do not have EGFR mutations or ALK-positive NSCLC; adjuvant treatment

Result of dossier assessment:

Added benefit not proven

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Project no. Title Status
A17-50 Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V Commission completed
A17-52 Atezolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V Commission completed
A17-51 Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V Commission completed
A18-88 Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V (new scientific findings) Commission completed
A19-81 Atezolizumab (breast cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A19-83 Atezolizumab (NSCLC; combination with bevacizumab, carboplatin and paclitaxel) – Benefit assessment according to §35a Social Code Book V Commission completed
A19-84 Atezolizumab (NSCLC; combination with nab-paclitaxel and carboplatin) – Benefit assessment according to §35a Social Code Book V Commission completed
A19-86 Atezolizumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A20-97 Atezolizumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V Commission completed
A21-69 Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V Commission completed
A22-124 Atezolizumab (NSCLC, adjuvant) - Addendum to Commission A22-67 Commission completed

Federal Joint Committee (G-BA)

2023-01-05 A G-BA decision was published.

G-BA documents on this decision

Contact

Press contact

+49 221 356850

presse@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page